MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1007/s11255-021-02965-w

Медицинская библиотека · International urology and nephrology · 2021

Long-acting erythropoiesis-stimulating agent (ESA) induces physiological erythropoiesis via improvement of iron availability.

Masumoto Miwa, Kuragano Takahiro, Takata Chisa, Fukui Risako, Mihara Yuki, Okamoto Rina, Iwasaki Takahide, Ookawa Satoshi, Aichi Makoto, Yahiro Mana, Kida Arithoshi, Nanami Masayshi

СтатьяПеревод пока не подготовлен

Аннотация

PURPOSE: Previous studies reported that the long-acting erythropoiesis-stimulating agent (ESA) significantly suppresses the expression of hepcidin, which regulates iron availability. In this study, we compared the iron availability for erythropoiesis between short and long-acting ESA over a long period.

METHODS

We enrolled 69 hemodialysis patients in this study. All patients were treated with short-acting ESA (epoetin-α or epoetin-β) for the first 30 months. Then, all patients switched to long-acting ESA (continuous erythropoietin receptor activator-methoxy polyethylene glycol-epoetin beta) for the next 30 months. We measured their blood levels of Hb, ferritin, iron, total iron-binding capacity, intact-parathyroid hormone, calcium, phosphate, albumin, and highly sensitive CRP level.

RESULTS

There was no significant change in the dose of short or long-acting ESA during the study period. Compared with the short-acting ESA period, the mean hemoglobin (Hb) and transferrin saturation levels were significantly increased in the long-acting ESA period (from 10.3 ± 0.2 to 10.6 ± 0.3 g/dL). On the other hand, the mean serum ferritin level (from 72 ± 22.2 to 56.3 ± 14 ng/mL) and the dose of IV iron (from 108 ± 63 to 53 ± 27 mg/month) were significantly decreased in the long-acting ESA period.

CONCLUSION

In this study, we found that anemia treatment with long-acting ESA attenuated the iron utilization for erythropoiesis and maintained target Hb levels without requiring a higher dose of IV iron or ESA.

Для цитирования: Masumoto Miwa, Kuragano Takahiro, Takata Chisa, Fukui Risako, Mihara Yuki, Okamoto Rina, Iwasaki Takahide, Ookawa Satoshi, Aichi Makoto, Yahiro Mana, Kida Arithoshi, Nanami Masayshi. Long-acting erythropoiesis-stimulating agent (ESA) induces physiological erythropoiesis via improvement of iron availability.. International urology and nephrology. 2021. DOI: 10.1007/s11255-021-02965-w.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.